Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

Provided By Globe Newswire

Last update: May 5, 2022

Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements

Maintains strong financial position while advancing and expanding development portfolio